207.80 +0.50 (0.24%)
Pre-market: 9:27AM EDT
Dr. Kathleen Jordan, SVP of Medical Affairs at Tia, joins Yahoo Finance’s Kristin Myers and Alexis Christoforous to discuss the latest on the coronavirus.
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the pre-print publication of data from a Phase 2b clinical trial in children demonstrating 77 percent efficacy for a malaria vaccine candidate, R21, created by the University of Oxford that includes Novavax' Matrix-M™ adjuvant and is licensed to Serum Institute of India (SII). Published online in Preprints with The Lancet, this vaccine's high levels of protective efficacy hold promise of becoming an important tool for global malaria eradication.
A trial of a malaria vaccine from the University of Oxford indicated it was 77 per cent effective — dramatically better than the existing shots for preventing one of the world’s most deadly diseases. The jab, known as R21, is the first that could surpass the World Health Organization goal of an available vaccine with at least 75 per cent efficacy by 2030. Mosquirix, the first malaria vaccine, which was initially deployed in 2015, took GSK more than 30 years to develop and was about 39 per cent effective over four years.